Is a mammography medical outcome audit required by law?

Yes. MQSA (the Mammography Quality Standards Act) requires all accredited mammography facilities to maintain a medical audit system. The audit must track all positive mammographic findings, correlate those findings with biopsy results and cancer outcomes, calculate key performance indicators, compare performance against published benchmarks, and analyze results at least annually. The results must be made available for review by the facility's lead interpreting physician and must be reviewable during FDA inspections.

What does a mammography medical outcome audit track?

A comprehensive mammography medical outcome audit tracks: all mammograms with a positive assessment (BI-RADS 0, 4, 5, and 3 with biopsy recommendation); associated biopsy recommendations and procedures; biopsy outcomes and pathology results (benign vs. malignant, histologic type, stage); cancer outcomes for detected lesions; follow-up completion status; and performance metrics including recall rate, cancer detection rate (CDR), positive predictive values (PPV1, PPV2, PPV3), sensitivity, specificity, and biopsy yield. Many facilities also track return rates, TAT (turnaround time), and density distribution.

What are the required performance metrics in a mammography audit?

Under MQSA, audit tracking must support calculation of the following metrics at minimum: recall rate (abnormal interpretation rate / AIR) — the percentage of screening mammograms assessed as BI-RADS 0; cancer detection rate (CDR) — cancers detected per 1,000 mammograms performed; positive predictive value 1 (PPV1) — cancers per 100 abnormal screening mammograms; positive predictive value 2 (PPV2) — cancers per 100 biopsies recommended from imaging; positive predictive value 3 (PPV3) — cancers per 100 tissue sampling procedures performed. Sensitivity and specificity are also standard components of a complete audit.

What are the ACR benchmark values for mammography audit metrics?

The American College of Radiology (ACR) and the Breast Cancer Surveillance Consortium (BCSC) publish regularly updated performance benchmarks. Current commonly referenced targets include: recall rate (AIR) of 5–12% for screening mammography; cancer detection rate of 2–7 cancers per 1,000 screening mammograms; PPV1 of 3–8%; PPV2 of 20–40%; sensitivity of 75–90%; specificity of 88–95%. Individual physician performance is compared against both national benchmarks and internal facility averages. Values significantly outside these ranges warrant focused review.

Who is responsible for conducting the mammography medical outcome audit?

MQSA places primary responsibility for the medical audit program on the facility and its lead interpreting physician. The lead interpreting physician is responsible for reviewing individual physician performance data, ensuring annual analysis occurs, and acting on findings that fall outside acceptable performance ranges. In practice, the day-to-day work of tracking findings, collecting pathology results, calculating metrics, and preparing audit reports is often performed by administrative staff, a radiology administrator, or an external audit support service. The interpreting physician remains responsible for reviewing, interpreting, and acting on the results.

How often must the mammography audit be analyzed?

MQSA requires that medical audit data be analyzed at least once every 12 months. This analysis must include comparison of each interpreting physician's performance data against established benchmarks and against the facility's internal performance averages. Many facilities conduct more frequent interim reviews — quarterly or semi-annually — to identify trends before they accumulate over a full year. For physicians with low mammography volume (a common issue in facilities that share interpreting physician time across multiple modalities), more frequent monitoring can be important because low case counts can make annual benchmarking statistically unstable.

What happens when audit metrics fall outside benchmark ranges?

When an interpreting physician's performance metrics fall outside nationally established benchmark ranges, MQSA requires the facility to take corrective action. The nature of the corrective action depends on the direction and magnitude of the deviation. A recall rate significantly above the upper benchmark may indicate over-calling; a recall rate below the lower benchmark may indicate under-calling. In either case, the facility is expected to document the finding, investigate potential causes, implement a corrective action plan, and follow up to verify improvement. The corrective action process and its documentation must be available for FDA inspection review.

What is a positive predictive value in mammography?

Positive predictive value (PPV) in mammography measures how often a positive assessment actually results in a cancer diagnosis. MQSA tracks three PPV levels: PPV1 measures cancers found among all women recalled from screening (BI-RADS 0 assessments that led to any imaging recommendation). PPV2 measures cancers found among all women for whom biopsy was recommended after diagnostic workup. PPV3 (also called biopsy yield) measures cancers found among all women who actually underwent tissue sampling. Together, the three PPV values give a layered picture of how efficiently the practice is converting assessments into confirmed diagnoses and how much benign tissue is being sampled relative to malignant.

What is the difference between recall rate and AIR?

Recall rate and Abnormal Interpretation Rate (AIR) refer to the same metric — the percentage of screening mammograms with an assessment that triggers a recommendation for additional evaluation (BI-RADS 0). Some sources use 'recall rate' loosely to describe any return for additional imaging from any cause, including same-day workup. For MQSA audit purposes, the precise term is Abnormal Interpretation Rate (AIR), calculated as the number of BI-RADS 0 assessments divided by the total number of screening mammograms interpreted. When a facility performs same-day diagnostic workup on screening patients (as some high-volume centers do), AIR calculation requires adjustment to avoid undercounting true screening recall activity.

What is cancer detection rate and why does it matter?

Cancer detection rate (CDR) is the number of breast cancers detected per 1,000 mammograms performed. It is one of the most direct measures of whether a screening program is succeeding at its primary purpose: finding breast cancer in the people being screened. A CDR significantly below the benchmark range may indicate under-detection — either through assessment practices that are missing findings or through population characteristics such as a low-prevalence screening population. CDR is directly related to recall rate and PPV: an unusually low CDR paired with a high recall rate can suggest a pattern of over-recalling patients without a corresponding improvement in cancer detection, which is one of the most important patterns a mammography audit is designed to surface.

What is the role of pathology correlation in the audit?

Pathology correlation is the process of connecting mammographic assessments that led to biopsy with the actual biopsy and pathology results. It is the foundation of all PPV calculations and cancer detection metrics. Without complete pathology correlation, audit metrics are mathematically incomplete and unreliable. Incomplete correlation is one of the most common audit problems — it occurs when biopsy procedures happen at a different facility than where the mammogram was interpreted, when pathology results are reported to a different provider, or when the facility lacks a systematic process for retrieving and recording pathology results. A robust audit program has a defined, consistent workflow for retrieving pathology outcomes for every biopsy recommendation the facility generates.

How does Mammologix support the medical outcome audit requirement?

Mammologix supports breast imaging facilities with the full cycle of mammography medical outcome audit operations: tracking positive assessments, monitoring follow-up completion, documenting biopsy recommendations and procedures, collecting and correlating pathology results, calculating MQSA-required performance metrics, generating facility-level and physician-level outcome reports, comparing performance against ACR and BCSC benchmarks, and producing annual audit documentation in a format ready for internal review and FDA inspection. Mammologix has supported mammography audit programs since 1995 and serves facilities ranging from single-location practices to multi-site health system programs.

Definitional Guide

What Is a Mammography Medical Outcome Audit?

Q: What is a mammography medical outcome audit?

A mammography medical outcome audit (sometimes called MMOA or simply a mammography audit) is a structured process that tracks the outcomes of mammographic assessments and correlates them with pathology results and biopsy findings. MQSA requires every accredited mammography facility to maintain a medical audit system. The purpose of the audit is to allow interpreting physicians and facility leadership to evaluate the accuracy of mammographic assessments and identify opportunities to improve screening and diagnostic performance.

The MQSA-required audit that tracks the accuracy of mammographic assessments — what it measures, how it works, and what the metrics mean.

MQSA RequiredAnnual AnalysisPer-Physician TrackingACR Benchmarked

The Audit in Plain Language

A mammography medical outcome auditis a systematic, ongoing tracking process that every MQSA-accredited mammography facility is required to maintain. Its purpose is straightforward: to measure how accurately the facility’s interpreting physicians are assessing mammograms by comparing what they said was there against what biopsy and pathology results showed was actually there.

When a radiologist interprets a mammogram and recommends additional imaging or biopsy, the audit tracks what happened next. Did the patient get the biopsy? Was the finding malignant or benign? How often does this physician’s recommendation for additional workup result in a confirmed cancer diagnosis? Over a population of patients, these outcomes reveal patterns — patterns that are not visible case-by-case but that matter enormously at the program level.

The audit is the mechanism by which a breast imaging program can answer the most important question it faces: Is this program finding breast cancer at the rate it should, without recalling more patients than necessary?

The Core Audit Metrics

MQSA requires calculation and tracking of these performance measures at minimum — per physician and per facility.

Recall Rate / AIR

Abnormal Interpretation Rate — percentage of screening mammograms assessed BI-RADS 0 (additional imaging needed).

ACR target: 5–12%

Cancer Detection Rate

Number of breast cancers detected per 1,000 mammograms performed.

ACR target: 2–7 per 1,000

PPV1

Positive Predictive Value 1 — cancers found per 100 abnormal screening interpretations.

ACR target: 3–8%

PPV2

Positive Predictive Value 2 — cancers found per 100 biopsies recommended after diagnostic workup.

ACR target: 20–40%

PPV3 / Biopsy Yield

Positive Predictive Value 3 — cancers found per 100 tissue sampling procedures performed.

ACR target: varies by procedure type

Sensitivity & Specificity

Sensitivity: cancers detected as a proportion of all cancers present. Specificity: normal studies correctly called negative.

ACR: sensitivity 75–90%, specificity 88–95%

What a Compliant Audit Program Requires

1

Track every positive assessment

Every mammogram with a BI-RADS 0, 4, or 5 assessment (and BI-RADS 3 cases with biopsy recommendation) must be entered into the audit tracking system. This is the input side of the audit — if a positive finding is not captured, it cannot be correlated with its outcome.

2

Monitor follow-up completion

For every positive assessment, the audit must track whether the recommended follow-up (additional imaging or biopsy) occurred. Patients who are lost to follow-up represent both a patient safety concern and an audit data gap. Systematic follow-up monitoring is the operational foundation of a reliable audit.

3

Collect and correlate pathology results

For every biopsy that occurs as a result of a mammographic recommendation, the audit must capture the pathology result — benign or malignant — and link it to the originating mammographic assessment and the interpreting physician who made the recommendation. Incomplete pathology correlation is the most common reason audits fail to support accurate metric calculation.

4

Calculate metrics by physician and by facility

MQSA requires that performance metrics be calculated at both the individual interpreting physician level and the aggregate facility level. Each physician must be able to see how their own recall rate, CDR, and PPV values compare to internal averages and national benchmarks.

5

Analyze annually and compare to benchmarks

Audit data must be formally analyzed at least once per year. The analysis must include comparison to ACR/BCSC benchmarks, identification of physicians whose performance falls outside expected ranges, documentation of findings, and any required corrective action.

6

Document and retain for FDA inspection

All audit records — tracking data, metric calculations, annual analyses, and any corrective action documentation — must be retained and made available for review during FDA MQSA inspections.

Frequently Asked Questions

Medical Outcome Audit Support from Mammologix

Mammologix has supported mammography medical outcome audit programs since 1995. Our audit support includes end-to-end tracking, pathology correlation workflows, metric calculation, physician-level reporting, benchmark comparison, and annual audit documentation — delivered as ready-to-use output, not raw data for your staff to process.

MammoTrackPatient tracking, outcome monitoring, and audit-ready documentation.MammoComplyMQSA compliance support, audit preparation, and inspection readiness.What Is MQSA?The complete guide to the Mammography Quality Standards Act.AIR Score CalculatorCalculate your Abnormal Interpretation Rate vs. ACR benchmarks.

Talk to Mammologix About Audit Support Explore MammoTrack

About the Author

RL

Richard “Rick” Lippert Jr.

ARRT · President & Founder, Mammologix · Breast Imaging Operations since 1995

A registered radiologic technologist and founder of Mammologix, Rick Lippert has spent more than 30 years in breast imaging operations — from clinical practice and hospital radiology administration to building specialized service platforms for imaging centers nationwide. His work spans mammography tracking, lay communication, FDA/MQSA-related support, medical outcome audit, and the operational systems that help facilities stay compliant and keep patients from falling through the cracks.

View full bio →